Vitamin D Metabolites in Nonmetastatic High-Risk Prostate Cancer Patients with and without Zoledronic Acid Treatment after Prostatectomy
There are limited and discrepant data on prostate cancer (PCa) and vitamin D. We investigated changes in three vitamin D<sub>3</sub> metabolites in PCa patients after prostatectomy with zoledronic acid (ZA) treatment regarding their metastasis statuses over four years. In 32 patients fro...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/6/1560 |
| _version_ | 1797446907087290368 |
|---|---|
| author | Carsten Stephan Bernhard Ralla Florian Bonn Max Diesner Michael Lein Klaus Jung |
| author_facet | Carsten Stephan Bernhard Ralla Florian Bonn Max Diesner Michael Lein Klaus Jung |
| author_sort | Carsten Stephan |
| collection | DOAJ |
| description | There are limited and discrepant data on prostate cancer (PCa) and vitamin D. We investigated changes in three vitamin D<sub>3</sub> metabolites in PCa patients after prostatectomy with zoledronic acid (ZA) treatment regarding their metastasis statuses over four years. In 32 patients from the ZEUS trial, 25(OH)D<sub>3</sub>, 24,25(OH)<sub>2</sub>D<sub>3</sub>, and 1,25(OH)<sub>2</sub>D<sub>3</sub> were measured with liquid chromatography coupled with tandem mass spectrometry at four time points. All the patients received daily calcium and vitamin D<sub>3</sub>. Bone metastases were detected in 7 of the 17 ZA-treated patients and in 5 of the 15 controls (without ZA), without differences between the groups (<i>p</i> = 0.725). While 25(OH)D<sub>3</sub> and 24,25(OH)<sub>2</sub>D<sub>3</sub> increased significantly after the study’s start, with following constant values, the 1,25(OH)<sub>2</sub>D<sub>3</sub> concentrations remained unchanged. ZA treatment did not change the levels of the three metabolites. 25(OH)D<sub>3</sub> and 24,25(OH)<sub>2</sub>D<sub>3</sub> were not associated with the development of bone metastases. In contrast, 1,25(OH)<sub>2</sub>D<sub>3</sub> was also higher in patients with bone metastasis before the study’s start. Thus, in high-risk PCa patients after prostatectomy, 25(OH)D<sub>3</sub>, 24,25(OH)<sub>2</sub>D<sub>3</sub>, and 1,25(OH)<sub>2</sub>D<sub>3</sub> were not affected by supportive ZA treatment or by the development of metastasis over four years, with the exception of 1,25(OH)<sub>2</sub>D<sub>3</sub>, which was constantly higher in metastatic patients. There might be potential prognostic value if the results can be confirmed. |
| first_indexed | 2024-03-09T13:47:20Z |
| format | Article |
| id | doaj.art-917249989c44459d8fdbf60d666ff0e0 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T13:47:20Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-917249989c44459d8fdbf60d666ff0e02023-11-30T20:57:08ZengMDPI AGCancers2072-66942022-03-01146156010.3390/cancers14061560Vitamin D Metabolites in Nonmetastatic High-Risk Prostate Cancer Patients with and without Zoledronic Acid Treatment after ProstatectomyCarsten Stephan0Bernhard Ralla1Florian Bonn2Max Diesner3Michael Lein4Klaus Jung5Department of Urology, Charité-Universitätsmedizin Berlin, 10115 Berlin, GermanyDepartment of Urology, Charité-Universitätsmedizin Berlin, 10115 Berlin, GermanyImmundiagnostik AG, 64625 Bensheim, GermanyImmundiagnostik AG, 64625 Bensheim, GermanyDepartment of Urology, Sana Medical Center Offenbach, 63069 Offenbach am Main, GermanyDepartment of Urology, Charité-Universitätsmedizin Berlin, 10115 Berlin, GermanyThere are limited and discrepant data on prostate cancer (PCa) and vitamin D. We investigated changes in three vitamin D<sub>3</sub> metabolites in PCa patients after prostatectomy with zoledronic acid (ZA) treatment regarding their metastasis statuses over four years. In 32 patients from the ZEUS trial, 25(OH)D<sub>3</sub>, 24,25(OH)<sub>2</sub>D<sub>3</sub>, and 1,25(OH)<sub>2</sub>D<sub>3</sub> were measured with liquid chromatography coupled with tandem mass spectrometry at four time points. All the patients received daily calcium and vitamin D<sub>3</sub>. Bone metastases were detected in 7 of the 17 ZA-treated patients and in 5 of the 15 controls (without ZA), without differences between the groups (<i>p</i> = 0.725). While 25(OH)D<sub>3</sub> and 24,25(OH)<sub>2</sub>D<sub>3</sub> increased significantly after the study’s start, with following constant values, the 1,25(OH)<sub>2</sub>D<sub>3</sub> concentrations remained unchanged. ZA treatment did not change the levels of the three metabolites. 25(OH)D<sub>3</sub> and 24,25(OH)<sub>2</sub>D<sub>3</sub> were not associated with the development of bone metastases. In contrast, 1,25(OH)<sub>2</sub>D<sub>3</sub> was also higher in patients with bone metastasis before the study’s start. Thus, in high-risk PCa patients after prostatectomy, 25(OH)D<sub>3</sub>, 24,25(OH)<sub>2</sub>D<sub>3</sub>, and 1,25(OH)<sub>2</sub>D<sub>3</sub> were not affected by supportive ZA treatment or by the development of metastasis over four years, with the exception of 1,25(OH)<sub>2</sub>D<sub>3</sub>, which was constantly higher in metastatic patients. There might be potential prognostic value if the results can be confirmed.https://www.mdpi.com/2072-6694/14/6/1560prostate cancerprostatectomyzoledronic acid treatmentvitamin Dcirculating vitamin D metabolites25(OH)D<sub>3</sub> |
| spellingShingle | Carsten Stephan Bernhard Ralla Florian Bonn Max Diesner Michael Lein Klaus Jung Vitamin D Metabolites in Nonmetastatic High-Risk Prostate Cancer Patients with and without Zoledronic Acid Treatment after Prostatectomy Cancers prostate cancer prostatectomy zoledronic acid treatment vitamin D circulating vitamin D metabolites 25(OH)D<sub>3</sub> |
| title | Vitamin D Metabolites in Nonmetastatic High-Risk Prostate Cancer Patients with and without Zoledronic Acid Treatment after Prostatectomy |
| title_full | Vitamin D Metabolites in Nonmetastatic High-Risk Prostate Cancer Patients with and without Zoledronic Acid Treatment after Prostatectomy |
| title_fullStr | Vitamin D Metabolites in Nonmetastatic High-Risk Prostate Cancer Patients with and without Zoledronic Acid Treatment after Prostatectomy |
| title_full_unstemmed | Vitamin D Metabolites in Nonmetastatic High-Risk Prostate Cancer Patients with and without Zoledronic Acid Treatment after Prostatectomy |
| title_short | Vitamin D Metabolites in Nonmetastatic High-Risk Prostate Cancer Patients with and without Zoledronic Acid Treatment after Prostatectomy |
| title_sort | vitamin d metabolites in nonmetastatic high risk prostate cancer patients with and without zoledronic acid treatment after prostatectomy |
| topic | prostate cancer prostatectomy zoledronic acid treatment vitamin D circulating vitamin D metabolites 25(OH)D<sub>3</sub> |
| url | https://www.mdpi.com/2072-6694/14/6/1560 |
| work_keys_str_mv | AT carstenstephan vitamindmetabolitesinnonmetastatichighriskprostatecancerpatientswithandwithoutzoledronicacidtreatmentafterprostatectomy AT bernhardralla vitamindmetabolitesinnonmetastatichighriskprostatecancerpatientswithandwithoutzoledronicacidtreatmentafterprostatectomy AT florianbonn vitamindmetabolitesinnonmetastatichighriskprostatecancerpatientswithandwithoutzoledronicacidtreatmentafterprostatectomy AT maxdiesner vitamindmetabolitesinnonmetastatichighriskprostatecancerpatientswithandwithoutzoledronicacidtreatmentafterprostatectomy AT michaellein vitamindmetabolitesinnonmetastatichighriskprostatecancerpatientswithandwithoutzoledronicacidtreatmentafterprostatectomy AT klausjung vitamindmetabolitesinnonmetastatichighriskprostatecancerpatientswithandwithoutzoledronicacidtreatmentafterprostatectomy |